MarketVue® Report
Spinal Cord Injury (SCI) (U.S.), 2021

Syndicated market assessment report driven by primary market research

REPORT STORE

Spinal Cord Injury (SCI) (U.S.), June 2021

DOWNLOAD SAMPLE REPORT
DOWNLOAD REPORT BROCHURE
The MarketVue®: Spinal Cord Injury (SCI) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
 
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
 
Topics covered in this report:
  • Disease overview: Review the disease pathophysiology and potential druggable targets
  • Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
  • Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
  • Unmet needs: Identify opportunities to address treatment or disease management gaps
  • Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
  • Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
 
Methodology:
Research for the MarketVue®: Spinal Cord Injury (SCI) report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research.
 
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
 
Key companies mentioned:
  • Kringle Pharma
  • Eusol Biotech
  • Acorda Therapeutics
  • AbbVie
  • Pharmazz
  • Mitsubishi Tanabe Pharma
  • ReNetX Bio
  • Histocell
  • Linage Cell Therapeutics
  • AlaMab Therapeutics
  • K Stem Cell (Biostar Stem Cell Research Institute)
  • InVivo Therapeutics
 
Key drugs mentioned:
  • Methylprednisolone
  • KP-100IT
  • ES 135
  • Fampridine-SR
  • Sovateltide / PMZ-1620 (Tycamzzi)
  • Elezanumab
  • MT-3921
  • AXER-204
  • HC016 Neurosave (FAB117-HC)
  • OPC1
  • ALMB-0166
  • AstroStem
  • Neuro-Spinal Scaffold
1. DISEASE OVERVIEW
A neurologic condition of loss of function and feeling
Overview
Table 1.1. American Spinal Cord Injury Association (ASIA) impairment scale
Acute and chronic spinal cord injury
Figure 1.2. symptoms of spinal cord injury
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. Prevalent cases of spinal cord injury by region, 2020
Table 2.1 Prevalence of spinal cord injury by country, US and EU5, 2020
Figure 2.2. Fast facts on spinal cord injury patient population.
3. CURRENT TREATMENT
Treatment goals
Figure 3.1. Primary goals of treating spinal cord injury
Standard of care
Figure 3.2. Percentage of patients who undergo surgery
Diagnosis and treatment flow
Figure 3.3. Diagnosis and treatment flow for spinal cord injury
Drug-treatment rates
Figure 3.4. Treating physicians and their patient load
Is there a role for therapeutic hypothermia in SCI
Figure 3.5. Percentage of acute SCI patients receiving therapeutic hypothermia
Treating physicians and their patient load
Figure 3.6. Professionals involved in spinal cord injury patient care
Figure 3.7. Neurologist SCI patient load
Must-know treatment dynamics
Evolution of treatment
Figure 3.8. Potential timeline of spinal cord injury market development
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in spinal cord injury
Figure 4.2. Physician rankings of unmet needs in spinal cord injury
Additional neurosurgeon commentary on unmet needs.
Barriers to care
Figure 4.3 Percent of neurologists ranking barrier as “impactful” to optimal spinal cord injury care.
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Percentage of neurologists who rated emerging target or approach as “promising”
Figure 5.2. Percentage of neurologists ranking product attribute among top three most important
Figure 5.3. Number of emerging therapies addressing unmet needs in SCI
Table 5.1. Emerging clinical-stage therapies for SCI
Figure 5.4. Neurologists’ awareness of emerging spinal cord injury therapies
6. VALUE & ACCESS
Overview
Figure 6.1. Payer mix for spinal cord injury
Healthcare costs and living expenses of SCI patients
Figure 6.2. Yearly expenses (health care costs and living expenses)
Table 6.1. Yearly expenses (health care costs and living expenses)
Table 6.2. Categories of healthcare costs for SCI and areas of potential impact of new therapies
7. METHODOLOGY
Primary market research methodology
Epidemiology methodology
What is the difference between purchasing a published report and requesting a new report?

Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.

How does REACH produce new primary market research reports in 15 business days?

By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.

Who writes REACH reports?

Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.

Does REACH cover both rare and non-rare diseases?

REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.

Can I meet with the team to discuss the report?

Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.

Published Report

Download immediately.


New Report

Updated upon purchase. Delivered in 15 days.


Undecided about purchasing this report?

» Inquire before buying

Reach out to learn more about report bundle discounts

Reach out to our team to learn more about our capabilities and view sample reports.

Contact us